We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV

By LabMedica International staff writers
Posted on 30 Jun 2026

Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. More...

In England, about one in 20 people living with HIV are unaware of their status, underscoring persistent gaps in routine screening pathways. New findings now demonstrate how a large-scale emergency department opt-out testing initiative is detecting infections earlier and linking patients to care.

The UK National Health Service (NHS) Blood Borne Virus Opt-Out Testing Program is a first-of-its-kind large-scale initiative operating in hospital emergency departments (EDs). Adults attending EDs in 88 towns and cities with high HIV prevalence who are already having blood drawn are routinely tested for HIV, hepatitis B, and hepatitis C unless they opt out. Individuals with positive results are then offered specialist support and a treatment plan.

According to the latest NHS data, the program has identified 1,900 previously undiagnosed HIV cases since it launched in April 2022. An economic evaluation published in The Lancet HIV and led by the University of Bristol and the National Institute for Health and Care Research (NIHR) estimated that 802 diagnoses from the program’s initial phase could avert about 187 HIV-related deaths and 28 new infections over 20 years.

Research by the UK Health Security Agency (UKHSA) found that 93% of newly diagnosed individuals reached by the initiative had no record of a prior HIV test, indicating that the model is engaging people unlikely to be tested through other pathways.

The study concluded the approach offers good value for the NHS, citing a low per-test cost and the clinical benefits of earlier diagnosis and treatment initiation. The program forms part of national efforts to reduce HIV transmission, with NHS leaders continuing the rollout and three additional hospitals expected to begin ED testing by April 2027. The government’s HIV Action Plan 2025–2030 also sets out continued investment to sustain opt-out testing for HIV, hepatitis B, and hepatitis C in high-prevalence areas.

“At around £6 per HIV test, the program is good value for money for the NHS, and importantly has led to linkage to treatment to improve the health and lifespan of many people who were previously living with undiagnosed HIV,” said Dr. Josephine Walker, lead author at the University of Bristol and NIHR Health Protection Research Unit in Evaluation and Behavioural Science.

“Knowing your HIV status is as important as checking your blood pressure, and our pioneering NHS Blood Borne Virus Opt-Out Testing Program is helping hundreds of people get a diagnosis—often before they have any symptoms at all—which means they have access to life-saving treatment," said Professor Francesca Swords, national medical director for the NHS.

"NHS staff are committed to improving early detection of HIV and other blood-borne viruses, and improving awareness of these health conditions to reduce the chance of people unknowingly passing it on to others. The successful rollout of this initiative in hospital EDs is an excellent example of how the NHS is working to make every contact with patients matter by supporting people to stay well, access treatment, save lives and make the best use of its resources,” added Prof. Swords.

Related Links
University of Bristol 
NIHR


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Portable POCT Blood Gas Analyzer
BD100
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.